• Aucun résultat trouvé

[PDF] Top 20 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

Has 10000 "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis" found on our website. Below are the top 20 most common "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis".

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

... x The Spinal Osteoporosis Therapeutic Intervention study investigators were as follows: Australia : ...University of Louvain, Brussels; J.M. Kaufman, University of Gent, Gent; ...Hospital ... Voir le document complet

10

Strontium ranelate decreases the risk of hip fracture over 3 and 5 years in post menopausal women at high risk

Strontium ranelate decreases the risk of hip fracture over 3 and 5 years in post menopausal women at high risk

... Objectives: Strontium ranelate is an effective anti-osteoporotic treatment with a unique mode of action increasing bone formation while decreasing bone ...efficacy of strontium ... Voir le document complet

1

The Treatment of Severe Postmenopausal Osteoporosis : A Review of Current and Emerging Therapeutic Options

The Treatment of Severe Postmenopausal Osteoporosis : A Review of Current and Emerging Therapeutic Options

... fractures in patients Abstract with ...previous fracture are at high risk for subsequent vertebral or hip fracture, it is of prime importance to treat such patients ... Voir le document complet

9

Association between changes in bone mineral density and vertebral fracture incidence in untreated postmenopausal women : a 3-year prospective study

Association between changes in bone mineral density and vertebral fracture incidence in untreated postmenopausal women : a 3-year prospective study

... that, in untreated patients, low bone mineral density (BMD) is consistently correlated with increased fracture ...assessed the relationship between bone loss over time and fracture ... Voir le document complet

1

Cost-effectiveness of buffered soluble alendronate 70mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

Cost-effectiveness of buffered soluble alendronate 70mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

... Treatments In base case, the effects of treatment on the risk of fractures (expressed as relative risks, RR) were derived from the most recent network meta-analysis ... Voir le document complet

12

Positive effects of strontium ranelate on spine osteoarthritis progression

Positive effects of strontium ranelate on spine osteoarthritis progression

... ranelate in the treatment of postmenopausal ...On the lateral spine radiograph, four inter-vertebral spaces ...for the presence and severity of osteophytes, ... Voir le document complet

1

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

... exploring the association between BMD changes and fracture reduction have been mainly conducted with antiresorptive agents (30 –32), but have yielded contradictory results (12, ...Among women ... Voir le document complet

6

Effects of Strontium Ranelate on Spinal Osteoarthritis Progression

Effects of Strontium Ranelate on Spinal Osteoarthritis Progression

... TReatment Of Peripheral OSteoporosis (TROPOS) trials performed on 1105 women with osteoporosis and concomitant radiological spinal OA at baseline, and for whom lumbar x-rays were ... Voir le document complet

6

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study

... List of investigators: FRANCE: ...University of Louvain, Brussels; ...Sorensen, The Osteoporosis Research Center, Hvidovre; ...M. Osteoporosis Centre, Odense; ...Centre of ... Voir le document complet

7

Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fractures status

Strontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fractures status

... Background: The anti-fracture efficacy of strontium ranelate 2g/day, a new orally active anti-osteoporotic agent with an innovative mode of action both increasing bone ... Voir le document complet

1

Ultrasound assessment of the intima and media layers on the carotid arteries in peri- and postmenopausal women

Ultrasound assessment of the intima and media layers on the carotid arteries in peri- and postmenopausal women

... measure the thickness of intima and media layers of carotid arteries of peri- and post-menopausal women using standard ultrasound equipment present in many Ob & Gyn ... Voir le document complet

1

Potential of pomegranate and its derivatives for the prevention of bone loss in a preclinical mice model of postmenopausal osteoporosis

Potential of pomegranate and its derivatives for the prevention of bone loss in a preclinical mice model of postmenopausal osteoporosis

... Potential of pomegranate and its derivatives for the prevention of bone loss in a preclinical mice model of postmenopausal osteoporosis Mélanie Spilmont, Laurent Leotoing, ... Voir le document complet

2

Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.

Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.

... that the +331G/A hPR polymorphism may be not functional in endothelial and smooth muscle cells of the vessel ...studied in vitro in endometrial cancer cells ...that the ... Voir le document complet

12

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.

... Meta-analysis of observational studies showed that oral but not transdermal oestrogen increased the risk of venous ...Compared with non-users, odds ratios (95 % confidence interval) ... Voir le document complet

35

Failure in osteoporosis management after hip fracture

Failure in osteoporosis management after hip fracture

... management of osteoporosis after hip fracture is a ...hip fracture whereas mortality reaches rates which are comparable to those reported 20 years ago and more than half of the ... Voir le document complet

30

Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.

Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.

... limitation of our study is that observational studies are subject to bias. The validity of the ESTHER study has already been discussed (3, 4, ...13). In the present analysis, ... Voir le document complet

7

Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment

Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment

... treated women to increased fracture risk. Determinants of poor adherence are poorly ...understood. The study aims to determine physician- and patient- rated treatment compliance ... Voir le document complet

9

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

... 8556 women between the ages of 59 and 80 years with a BMD T-score of ...at the lumbar spine; a prevalent vertebral fracture was not an entry re- quirement and only ... Voir le document complet

15

Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women

Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women

... highlights the need to improve clinical management of the menopause in women with ...17) of our patients reported disabling hot flushes, and none of them had a ... Voir le document complet

9

Two-year efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: the MOBILE study

Two-year efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: the MOBILE study

... Result Content View [2005] [OP0036] TWO-YEAR EFFICACY AND TOLERABILITY OF ONCE-MONTHLY ORAL IBANDRONATE IN POSTMENOPAUSAL OSTEOPOROSIS: THE MOBILE STUDY C. Cooper 1 , P.D. Delmas 2 , ... Voir le document complet

2

Show all 10000 documents...